Results 41 to 50 of about 169,886 (331)

Clinical value of sentinel lymph node biopsy in patients with cutaneous and acral melanoma [PDF]

Zhongguo aizheng zazhi, 2022
Background and purpose: For cutaneous and acral malignant melanoma, sentinel lymph node biopsy (SLNB) is an effective tool to evaluate the situation of regional lymph node metastasis and to determine the pathological stage.
ZOU Zijian, SUN Wei, HU Tu, WANG Chunmeng, YAN Wangjun, LUO Zhiguo, LIU Xin, ZHONG Jingqin, LIN Xinyi, XU Yu, CHEN Yong
doaj   +1 more source

Neuroendocrine Tumor Markers

Frontiers in Neuroendocrinology, 2001
Tumor markers used in the diagnosis and follow-up of patients with neuroendocrine tumors are in most instances not specific for a given tumor and circulate under normal conditions in the serum, making their use as an early diagnostic tool difficult (low sensitivity).
Lamberts, S.W.J., Hofland, Leo, Nobels, FRE   +2 more
openaire   +2 more sources

Discussing motherhood when the oncological prognosis is dire: ethical considerations for physicians

ESMO Open, 2020
Physicians are increasingly open to discussing and supporting pregnancy after cancer treatment. However, counselling patients who are seeking pregnancy despite advanced oncological disease and/or uncertain prognosis is still challenging. Two paradigmatic
Francesca Spada, Alma Linkeviciute, Nicola Fazio, Fedro A Peccatori   +3 more
doaj   +1 more source

Multimodality imaging differentiation of pancreatic neuroendocrine tumors and solid pseudopapillary tumors with a nomogram model: A large single-center study

Frontiers in Surgery, 2022
BackgroundPancreatic neuroendocrine tumors (pNETs) and solid pseudopapillary tumors (SPTs) are two of the most common pancreatic neoplasms with different treatment procedures.
Hai-Feng Hu, Hai-Feng Hu, Hai-Feng Hu, Hai-Feng Hu, Hai-Feng Hu, Zheng Li, Zheng Li, Zheng Li, Zheng Li, Zheng Li, Ke Chen, Meng-Qi Liu, Meng-Qi Liu, Meng-Qi Liu, Meng-Qi Liu, Meng-Qi Liu, Zeng Ye, Zeng Ye, Zeng Ye, Zeng Ye, Zeng Ye, Xue-min Chen, Yue Zhang, Xian-Jun Yu, Xian-Jun Yu, Xian-Jun Yu, Xian-Jun Yu, Xian-Jun Yu, Xiao-Wu Xu, Xiao-Wu Xu, Xiao-Wu Xu, Xiao-Wu Xu, Xiao-Wu Xu, Shun-Rong Ji, Shun-Rong Ji, Shun-Rong Ji, Shun-Rong Ji, Shun-Rong Ji   +37 more
doaj   +1 more source

The novel mTOR inhibitor RAD001 (Everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells [PDF]

, 2007
Background/Aim: Tumors exhibiting constitutively activated PI(3) K/Akt/mTOR signaling are hypersensitive to mTOR inhibitors such as RAD001 (everolimus) which is presently being investigated in clinical phase II trials in various tumor entities, including
Albert JM, Auernhammer CJ, Boulay A, Boulay A, Bousquet C, Burkhard Göke, Cao C, Christoph J. Auernhammer, Enrico N. De Toni, Faivre S, Gerald Spöttl, Grewe M, Heinrich H.D. Meyer, Hosoi H, Jeng YJ, Jennifer Meinecke, Kathrin Zitzmann, Kawamata S, Kirchner GI, Luo J, O?Reilly KE, Oberg K, Ramage JK, Sawyers CL, Shah T, Shaw RJ, Stephan Brand, Sun SY, Vignot S, von Wichert G, Wang L, Wanner K, Wendel HG, Wullschleger S, Yao JC, Yee KW   +35 more
core   +1 more source

Blood Transcript Profiling for the Detection of Neuroendocrine Tumors: Results of a Large Independent Validation Study

Frontiers in Endocrinology, 2018
Background: Available neuroendocrine biomarkers are considered to have insufficient accuracy to discriminate patients with gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) from healthy controls.
Mark J. C. van Treijen, Mark J. C. van Treijen, Catharina M. Korse, Catharina M. Korse, Rachel S. van Leeuwaarde, Rachel S. van Leeuwaarde, Lisette J. Saveur, Lisette J. Saveur, Menno R. Vriens, Menno R. Vriens, Wieke H. M. Verbeek, Wieke H. M. Verbeek, Margot E. T. Tesselaar, Margot E. T. Tesselaar, Gerlof D. Valk, Gerlof D. Valk   +15 more
doaj   +1 more source

Neuroendocrine tumor theranostics

Cancer Science, 2022
AbstractTheranostics is a term coined by combining the words “therapeutics” and “diagnostics,” referring to single chemical entities developed to deliver therapy and diagnosis simultaneously. Neuroendocrine tumors are rare cancers that occur in various organs of the body, and they express neuroendocrine factors such as chromogranin A and somatostatin ...
Yasushi Ichikawa, Noritoshi Kobayashi, Shoko Takano, Ikuma Kato, Keigo Endo, Tomio Inoue   +5 more
openaire   +2 more sources

Therapeutic sequences in patients with grade 1−2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group [PDF]

, 2019
Purpose: Many different treatments are suggested by guidelines to treat grade 1−2 (G1−G2) neuroendocrine tumors (NET). However, a precise therapeutic algorithm has not yet been established.
Badalamenti, G., Bianco, A., Colao, A., De Divitiis, C., Di Maio, S., Di Sarno, A., Dolce, P., Faggiano, A., Guarnotta, V., Leo, S., Mocerino, C., Modica, R., Ottaviano, M., Palmieri, G., Puliafito, I., Riccardi, F., Tafuto, S., Tozzi, L.   +17 more
core   +1 more source

NETest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and correlates with imaging

Endocrine Connections, 2019
Introduction: Current monoanalyte biomarkers are ineffective in gastroenteropancreatic neuroendocrine tumors (GEP-NETs). NETest, a novel multianalyte signature, provides molecular information relevant to disease biology.
Anna Malczewska, Magdalena Witkowska, Karolina Makulik, Agnes Bocian, Agata Walter, Joanna Pilch-Kowalczyk, Wojciech Zajęcki, Lisa Bodei, Kjell Oberg, Beata Kos-Kudła   +9 more
doaj   +1 more source

The molecular basis for ethnic variation and histological subtype differences in prostate cancer. [PDF]

, 2013
Prostate cancer is a common malignancy among men in Western countries. Recently the morbidity and mortality of prostate cancer increase dramatically in several oriental countries including China.
Goldstein, Andrew S, Huang, Jiaoti, Zong, Yang   +2 more
core   +1 more source